

For the management of Uncontrolled Type-2 Diabetes Mellitus

# LINAHENZ-D 5/10

Linagliptin 5 mg + Dapagliflozin 10 mg Tablets

## LINAHENZ-D 5/10

### Linagliptin 5 mg + Dapagliflozin 10 mg Tablets

#### **Background:**

The unmet need of achieving the HbA1c goal is strongly associated with the requirement for diverse therapeutic options. Due to its insulin-independent effects, dapagliflozin is used in combination with several other classes of antidiabetic medications. Evidence from numerous clinical trials suggest that SGLT2i and DPP4i FDCs are effective and safe in patients with T2DM. Compared with a DPP-4 inhibitor, the combined use of SGLT-2 inhibitor and DPP-4 inhibitor is significantly associated with a decrease in glycemic control, body weight and their advantages have already been proven. The combined use of dapagliflozin and linagliptin for managing T2DM is reasonable and attractive because of their different but complementary mechanisms of action.

#### Indication:

- Linahenz-D is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- In Treatment Naive Patients: When Metformin is contraindicated and HbA1c > 8%
- In Treatment Naive (with Metformin) patients: In combination with Metformin in patients where baseline HbA1c > 9%
- Uncontrolled on Metformin monotherapy: In patients uncontrolled on Metformin with HbA1c > 8.5%

#### Mechanism of Action:

- Linagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) to facilitate glucose regulation in response to a meal.
- Dapagliflozin inhibiting SGLT2 and blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.

#### Dosage & Administration:

Linahenz-D: One Tablet a day or as prescribed by the Doctors.

References:

1. Pharmaceutics. 2022 Mar; 14(3): 591.

2. Diabetes Ther (2022) 13:1097–1114

#### La Renon Healthcare Private Limited

E-mail: info@larenon.com | Web: www.larenon.com

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: +91-79-6616-8998, 2693-6656

Call me on:

Mail me at:

©2023 All rights reserved, La Renon Healthcare Private Limited